The effect of apoptotic cells on virus-specific immune responses detected using IFN-gamma ELISPOT

Journal of Immunological Methods

Volumn 357, Issue 1-2, 2010, Pages 51-54

  Lenders, Kevin ^a   Ogunjimi, Benson ^b   Beutels, Philippe ^b   Hens, Niel ^b,c   Van Damme, Pierre ^b   Berneman, Zwi N ^a   Van Tendeloo, Viggo F I ^a   Smits, Evelien L J M ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c HASSELT UNIVERSITY   (Belgium)

Author keywords

Apoptosis; Cellular immune response; ELISPOT; IFN gamma; Vaccine trial

Indexed keywords

7 AMINODACTINOMYCIN; CYTOMEGALOVIRUS ANTIGEN; CYTOMEGALOVIRUS ANTIGEN PP65; GAMMA INTERFERON; HERPES ZOSTER ANTIGEN; LIPOCORTIN 5; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; CELL COUNT; CELL LYSATE; CELL STIMULATION; CELL VIABILITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CRYOPRESERVATION; CYTOMEGALOVIRUS; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; NONHUMAN; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; STAINING; T LYMPHOCYTE; ULTRAVIOLET RADIATION; VARICELLA ZOSTER VIRUS; ADULT; BIOSYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOLOGY; MALE; METABOLISM; RADIATION EXPOSURE;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 3;

ADULT; ANTIGENS, VIRAL; APOPTOSIS; CRYOPRESERVATION; CYTOMEGALOVIRUS; FEMALE; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNOSORBENT TECHNIQUES; INTERFERON-GAMMA; MALE; T-LYMPHOCYTES; ULTRAVIOLET RAYS;

EID: 77952533489     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2010.03.001     Document Type: Article

References (9)

1. Akaike H. Information theory as an extension of the maximum likelihood principle. Second International Symposium on Information Theory 1973, 267. Akademiai Kiado, Budapest.
2. Firbas C., Jilma B., Tauber E., Buerger V., Jelovcan S., Lingnau K., Buschle M., Frisch J., Klade C.S. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine 2006, 24:4343.
3. Fowke K.R., Behnke J., Hanson C., Shea K., Cosentino L.M. Apoptosis: a method for evaluating the cryopreservation of whole blood and peripheral blood mononuclear cells. J. Immunol. Methods 2000, 244:139.
4. Janetzki, S., Panageas K.S., Ben Porat L., Boyer J., Britten C.M., Clay T.M., Kalos M., Maecker H.T., Romero P., Yuan J., Kast W.M., Hoos A. Results and harmonization guidelines from two large-scale international ELISPOT proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol. Immunother. 2008, 57:303.
5. Keating S.M., Bejon P., Berthoud T., Vuola J.M., Todryk S., Webster D.P., Dunachie S.J., Moorthy V.S., McConkey S.J., Gilbert S.C., Hill A.V. Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria. J. Immunol. 2005, 175:5675.
6. Levin M.J., Smith J.G., Kaufhold R.M., Barber D., Hayward A.R., Chan C.Y., Chan I.S., Li D.J., Wang W., Keller P.M., Shaw A., Silber J.L., Schlienger K., Chalikonda I., Vessey S.J., Caulfield M.J. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J.Infect.Dis. 2003, 188:1336.
7. Smith J.G., Liu X., Kaufhold R.M., Clair J., Caulfield M.J. Development and validation of a gamma interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus. Clin. Diagn. Lab. Immunol. 2001, 8:871.
8. Smith J.G., Joseph H.R., Green T., Field J.A., Wooters M., Kaufhold R.M., Antonello J., Caulfield M.J. Establishing acceptance criteria for cell-mediated-immunity assays using frozen peripheral blood mononuclear cells stored under optimal and suboptimal conditions. Clin. Vaccine Immunol. 2007, 14:527.
9. Verbeke G., Molenberghs G. Linear Mixed Models for Longitudinal Data 2001, Springer.